Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2020 / Small Molecules / JoyL Silva

JoyL Silva

General Manager at Pfizer CentreOne

  • Profile

Meet JoyL Silva

JoyL joined Pfizer more than 20 years ago and assumed the role of Pfizer CentreOne’s general manager in 2019. JoyL contributes to the industry by serving on the board of Pharma and Biopharma Outsourcing Association, a non-profit association that represents the needs of CDMOs in the US and is a frequent speaker at industry events and a published author.

Which people have inspired you?

The patients that I worked with as a nursing assistant while I was in college were a huge source of inspiration. Taking care of patients in a hospital  or a nursing home setting really puts into perspective what it means to develop and manufacture medicines when you see how powerful they can be.

What is the next big thing for the small molecule field?

I am excited to deliver on the innovative promise that small molecules are expected to bring to key therapeutic areas. The growth of highly potent APIs and the combined use of small molecules with ADCs represents an exciting opportunity for pharma and gives patients hope.  Given their evolving potency and complexity, the life science sector will continue to demand that we work alongside other areas of industry to deliver new specialized technologies so that targeted precision medicine is available when patients need it most.

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.